For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

Below, CNBC Select explains the differences between trademarks, copyrights and patents. Read on for more information and to ...

The last two decades have not been kind to science studies. Already bruised and battered by the “science wars” of the 1990s, ...

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ('NK-1”) antagonist ...

Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform of a novel PH1 payload. This payload is designed specifically to target and ...

How migrant professionals, innovators and researchers influence the world’s next wave of technological progress.

Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated ...

Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

Despite the importance of GoF modifications, they have sometimes faced misplaced concerns or opposition that could lead to their being overregulated or even banned.

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...

Although there are thousands of ETFs that owe their gains to Magnificent 7 AI stocks, these 2 ETFs have superior gains ...

If you’re a sci-fi fan or a university English student, you’ve probably come across this book once or twice in your life. The ...